{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:30:19Z","timestamp":1791538219898,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.berh.2018.01.001","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T10:23:10Z","timestamp":1519640590000},"page":"476-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Recent therapeutic advances in juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"31","author":[{"given":"Gabriella","family":"Giancane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rosina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Tibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2018.01.001_bib1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2018.01.001_bib2","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nrrheum.2013.105","article-title":"Advances from clinical trials in juvenile idiopathic arthritis","volume":"9","author":"Lovell","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3899\/jrheum.080560","article-title":"Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis","volume":"36","author":"Magnani","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3899\/jrheum.160173","article-title":"Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas","volume":"43","author":"Consolaro","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib6","first-page":"1989","article-title":"Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort","volume":"29","author":"Oen","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib7","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/1529-0131(200008)43:8<1858::AID-ANR23>3.0.CO;2-A","article-title":"Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis","volume":"43","author":"Guillaume","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/art.20860","article-title":"A\u00a0randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results","volume":"52","author":"Ruperto","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib9","first-page":"985","article-title":"Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension","volume":"33","author":"Reiff","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/rheumatology\/keh313","article-title":"Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial","volume":"43","author":"Zulian","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2018.01.001_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1546-0096-12-29","article-title":"Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry","volume":"12","author":"Sobel","year":"2014","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib12","first-page":"1918","article-title":"Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada","volume":"34","author":"Beukelman","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib13","first-page":"774","article-title":"A\u00a0reappraisal of intra-articular corticosteroid therapy in juvenile idiopathic arthritis","volume":"28","author":"Scott","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(17)30065-X","article-title":"Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial","volume":"389","author":"Ravelli","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2018.01.001_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.01.001_bib16","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A\u00a0randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.01.001_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.01.001_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2017-211108","article-title":"Learning the hard way: clinical trials in juvenile idiopathic arthritis","volume":"77","author":"Berard","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib20","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.berh.2018.01.001_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-540-73259-4_7","article-title":"Humanized antihuman IL-6 receptor antibody, tocilizumab","author":"Nishimoto","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.berh.2018.01.001_bib22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2018.01.001_bib23","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2018.01.001_bib24","first-page":"S5","article-title":"A4: efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: 2-year data from CHERISH","volume":"66","author":"Brunner","year":"2014","journal-title":"Arthritis rheumatol (Hoboken NJ)"},{"key":"10.1016\/j.berh.2018.01.001_bib25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2018.01.001_bib26","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2011.10.003","article-title":"Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis","volume":"142","author":"Dueckers","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.berh.2018.01.001_bib28","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3899\/jrheum.160074","article-title":"Management of juvenile idiopathic arthritis 2015: a position statement from the pediatric committee of the canadian rheumatology association","volume":"43","author":"Cellucci","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/rheumatology\/kep460","article-title":"BSPAR standards of care for children and young people with juvenile idiopathic arthritis","volume":"49","author":"Davies","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2018.01.001_bib30","first-page":"1063","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis","volume":"66","author":"Ringold","year":"2014"},{"key":"10.1016\/j.berh.2018.01.001_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1546-0096-11-5","article-title":"SHARE consortium. Time to share","volume":"11","author":"Wulffraat","year":"2013","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib32","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2018.01.001_bib33","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/art.21389","article-title":"Patterns of clinical remission in select categories of juvenile idiopathic arthritis","volume":"52","author":"Wallace","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib34","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis re er d","volume":"31","author":"Wallace","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib35","first-page":"S105","article-title":"Remission in juvenile idiopathic arthritis","volume":"24","author":"Ravelli","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib36","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/ard.2010.133033","article-title":"Juvenile idiopathic arthritis: state of the art and future perspectives","volume":"69","author":"Martini","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib37","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/art.27670","article-title":"Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kep459","article-title":"Developing standards of care for patients with juvenile idiopathic arthritis","volume":"49","author":"Wallace","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2018.01.001_bib39","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/rheumatology\/keq215","article-title":"Comment on: developing standards of care for patients with juvenile idiopathic arthritis","volume":"49","author":"Beresford","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2018.01.001_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2018.01.001_bib41","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1002\/art.23364","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"58","author":"Goekoop-Ruiterman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib42","first-page":"S209","article-title":"A\u00a0proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures","volume":"21","author":"Smolen","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib43","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2018.01.001_bib48","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib49","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib50","first-page":"6","article-title":"The new 2012 German recommendations for treating rheumatoid arthritis","volume":"72","author":"Wollenhaupt","year":"2013","journal-title":"Z\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib51","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib52","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.23916","article-title":"Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis","volume":"59","author":"Magni-Manzoni","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib53","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib54","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2012-202031","article-title":"Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis","volume":"72","author":"McErlane","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib55","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/art.34373","article-title":"Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score","volume":"64","author":"Consolaro","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib56","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/acr.22393","article-title":"Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score","volume":"66","author":"Consolaro","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2018.01.001_bib57","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/annrheumdis-2013-204186","article-title":"Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score","volume":"73","author":"Consolaro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib58","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.01.001_bib59","first-page":"S157","article-title":"Toward a treat-to-target approach in the management of juvenile idiopathic arthritis","volume":"30","author":"Consolaro","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","article-title":"Management of juvenile idiopathic arthritis: hitting the target","volume":"11","author":"Hinze","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib61","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.01.001_bib62","article-title":"Possible discontinuation of therapies after clinical remission in juvenile idiopathic arthritis","volume":"31","author":"Verazza","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib63","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3899\/jrheum.161078","article-title":"Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the childhood arthritis and rheumatology research alliance","volume":"44","author":"Horton","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.01.001_bib64","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrrheum.2012.30","article-title":"Advances and challenges in imaging in juvenile idiopathic arthritis","volume":"8","author":"Magni-Manzoni","year":"2012","journal-title":"Nat Rev Rheumatol"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:17:06Z","timestamp":1761499026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694218300019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1521694218300019"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2018.01.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent therapeutic advances in juvenile idiopathic arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2018.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}